Price range: $50.00 through $91.00
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog indicated for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy . As the first and only FDA-approved treatment for this specific condition, it works by stimulating the body’s natural production of growth hormone to reduce visceral adipose tissue . Available in 5mg and 10mg vial strengths for research purposes, Tesamorelin offers a targeted therapeutic approach to managing central fat accumulation associated with HIV
Looking to buy Tesamorelin for your research? Our lab-verified >98% pure Tesamorelin peptide is trusted by researchers worldwide for metabolic, adipose tissue, and IGF-1 research studies. In stock – ready to ship within 24 hours.
✅ Lab-Tested >98% Purity (COA Included)
✅ 5mg & 10mg Vials Available
✅ GH-Releasing Peptide Analog
✅ Fast, Discreet Shipping Worldwide
✅ Trusted by Leading Research Institutions
Tesamorelin (also known as TH9507) is a stabilized synthetic peptide analog consisting of the 44 amino acid sequence of human growth hormone-releasing factor (GRF). It functions by binding to and stimulating human GRF receptors on pituitary somatotroph cells, promoting the synthesis and pulsatile release of endogenous growth hormone (GH).
When you buy Tesamorelin from Mega Protide, you’re getting a research-grade peptide that has been third-party tested for purity and potency. This Tesamorelin research peptide is widely used in metabolic, adipose tissue, and IGF-1 research studies.
| Parameter | Details |
|---|---|
| Sequence | 44-amino acid GRF analog |
| Molecular Formula | C₂₂₁H₃₆₆N₇₂O₆₇S |
| Molecular Weight | ~5135.9 g/mol |
| CAS Number | 218949-48-5 |
| Form | Lyophilized powder |
| Quantity | 5mg or 10mg per vial |
| Purity | >98% by HPLC |
| Storage | Refrigerate at 2-8°C after reconstitution |
| Route | Subcutaneous injection |
| Half-Life | ~26-28 minutes |
Tesamorelin exerts its effects through the growth hormone (GH) axis:
| Mechanism | Effect |
|---|---|
| GRF Receptor Binding | Binds to human GRF receptors on pituitary somatotroph cells |
| GH Release | Promotes synthesis and pulsatile release of endogenous GH |
| IGF-1 Production | Increases insulin-like growth factor-1 (IGF-1) production |
| Lipolytic Effects | Reduces visceral adipose tissue (VAT) through GH-mediated lipolysis |
| Anabolic Effects | Increases lean body mass through GH-mediated anabolism |
| Metabolic Regulation | Modulates glucose and lipid metabolism |
Key Advantage: Tesamorelin is a stabilized GRF analog with a longer half-life than natural GRF, making it a valuable research tool for studying the GH-IGF-1 axis.
| Benefit | Research Application |
|---|---|
| GH-IGF-1 Axis Research | Studies on growth hormone release and IGF-1 production |
| Adipose Tissue Research | Investigations into visceral fat reduction and lipolysis |
| Metabolic Studies | Research on glucose metabolism, lipid profiles, and energy balance |
| Body Composition | Studies on lean body mass and fat distribution |
| Endocrinology | Research on pituitary function and hormonal regulation |
| HIV-Associated Lipodystrophy | Studies on fat redistribution in HIV patients |
Researchers choose to buy Tesamorelin from Mega Protide because of our commitment to quality and transparency.
| Application | Research Focus | Status |
|---|---|---|
| GH-IGF-1 Axis | Pituitary function, GH release, IGF-1 production | Well-established |
| Adipose Tissue | Visceral fat reduction, lipolysis, fat distribution | Clinical research |
| Metabolic Research | Glucose metabolism, insulin sensitivity, lipid profiles | Active research |
| Body Composition | Lean body mass, fat mass, muscle preservation | Clinical research |
| Endocrinology | Hormonal regulation, pituitary disorders | Active research |
| HIV Research | Lipodystrophy, fat redistribution, antiretroviral therapy | Clinical research |
| Study | Year | Finding |
|---|---|---|
| Falutz et al. | 2007 | Tesamorelin (2 mg/day) reduced visceral adipose tissue (VAT) by 27.71 cm² in HIV patients |
| Falutz et al. | 2010 | Tesamorelin showed significant reductions in trunk fat (-1.18 kg) and hepatic fat (-4.28%) |
| Stanley et al. | 2011 | Tesamorelin increased lean body mass by 1.42 kg without significant BMI changes |
| Mulligan et al. | 2013 | Tesamorelin demonstrated neutral glycemic profile with no significant glucose changes |
| Falutz et al. | 2014 | Long-term safety data supported continued use for VAT reduction |
| Verma et al. | 2017 | Meta-analysis confirmed Tesamorelin efficacy in reducing visceral adipose tissue |
| Rao et al. | 2020 | Tesamorelin showed potential for hepatic fat reduction in metabolic research |
📖 Over 15 years of peer-reviewed research support Tesamorelin research utility.
Add 1-2ml bacteriostatic water to the Tesamorelin vial
Gently swirl – do not shake
Refrigerate at 2-8°C
Use within 30 days of reconstitution
| Parameter | Recommendation |
|---|---|
| Standard Research Dose | 1.4 mg per injection (0.35 mL reconstituted solution) |
| Frequency | Once daily |
| Route | Subcutaneous injection |
| Half-Life | ~26-28 minutes |
| Storage | Refrigerate after reconstitution |
| Aspect | Details |
|---|---|
| Safety Profile | Well-tolerated; common side effects include arthralgia, injection site reactions |
| Side Effects | Arthralgia, injection site erythema/pruritus, peripheral edema, myalgia |
| Contraindications | Disruption of hypothalamic-pituitary axis, active malignancy, hypersensitivity |
| Warnings | May increase IGF-1 levels, cause fluid retention, glucose intolerance |
| Evidence Level | Strong clinical evidence for VAT reduction |
| Long-Term Data | Cardiovascular safety not fully established |
| Storage | Lyophilized: room temperature; Reconstituted: 2-8°C, use within 30 days |
| Advantage | Why It Matters |
|---|---|
| Lab-Verified >98% Purity | Third-party HPLC testing ensures quality and consistency |
| 5mg & 10mg Options | Flexible dosing for various research protocols |
| COA Included | Full transparency with every Tesamorelin order |
| Fast Shipping | Orders processed within 24 hours |
| Discreet Packaging | Privacy guaranteed |
Tesamorelin is supplied for research and laboratory use only. Not for human consumption. Not for therapeutic or diagnostic use. Use only by qualified researchers in controlled laboratory settings. Not FDA-approved for human use outside approved clinical protocols.
| Weight | 5mg, 10mg |
|---|
Always available!
Comes with each order!
Get access to expert resources.
Reviews
There are no reviews yet.